Current
2.2×
5-Year Average
3.3×
All-Time High
21.6×
All-Time Low
1.5×
P/B Ratio daily chart for Regeneron Pharmaceuticals (REGN)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/B Ratio for Regeneron Pharmaceuticals (REGN) from 2001 to 2025
| 2025 | $79.43B | $31.26B | 2.5× | -0.1× | |
| 2024 | $76.86B | $29.35B | 2.6× | -1.0× | |
| 2023 | $93.63B | $25.97B | 3.6× | +0.2× | |
| 2022 | $77.20B | $22.66B | 3.4× | -0.2× | |
| 2021 | $67.07B | $18.77B | 3.6× | -1.0× | |
| 2020 | $50.92B | $11.03B | 4.6× | +0.7× | |
| 2019 | $42.92B | $11.09B | 3.9× | -1.0× | |
| 2018 | $42.86B | $8.76B | 4.9× | -2.2× | |
| 2017 | $43.56B | $6.14B | 7.1× | -2.5× | |
| 2016 | $42.50B | $4.45B | 9.6× | -7.6× | |
| 2015 | $62.70B | $3.65B | 17.2× | -1.3× | |
| 2014 | $46.87B | $2.54B | 18.4× | -0.2× | |
| 2013 | $36.31B | $1.95B | 18.6× | +3.4× | |
| 2012 | $18.89B | $1.25B | 15.2× | +4.7× | |
| 2011 | $5.09B | $485.73M | 10.5× | +5.0× | |
| 2010 | $2.87B | $527.82M | 5.4× | +0.6× | |
| 2009 | $1.94B | $396.76M | 4.9× | +1.4× | |
| 2008 | $1.45B | $418.85M | 3.5× | -0.6× | |
| 2007 | $1.90B | $460.27M | 4.1× | -2.0× | |
| 2006 | $1.32B | $216.62M | 6.1× | -1.7× | |
| 2005 | $891.85M | $114.00M | 7.8× | +5.0× | |
| 2004 | $511.54M | $182.54M | 2.8× | -3.1× | |
| 2003 | $809.01M | $137.64M | 5.9× | +0.3× | |
| 2002 | $816.53M | $145.98M | 5.6× | +1.0× | |
| 2001 | $1.23B | $266.36M | 4.6× | — |
- 20252.5×
- 20242.6×
- 20233.6×
- 20223.4×
- 20213.6×
- 20204.6×
- 20193.9×
- 20184.9×
- 20177.1×
- 20169.6×
- 201517.2×
- 201418.4×
- 201318.6×
- 201215.2×
- 201110.5×
- 20105.4×
- 20094.9×
- 20083.5×
- 20074.1×
- 20066.1×
- 20057.8×
- 20042.8×
- 20035.9×
- 20025.6×
- 20014.6×
About P/B Ratio at Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (REGN) P/B ratio is 2.2× as of June 5, 2026. The 5-year average is 3.3×. The sector median currently stands at 3.4×. The current ratio is at the 10th percentile of its own 10-year history.
Regeneron Pharmaceuticals (REGN) historical P/B ratio has ranged from a low of 1.5× (2005) to a high of 21.6× (2012) in the available daily series.
The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.
Regeneron Pharmaceuticals P/B Ratio by Year
Regeneron Pharmaceuticals P/B Ratio 2025: 2.5×
Regeneron Pharmaceuticals (REGN) P/B ratio in 2025 was 2.5×, contracted from 2.6× the prior year.
Regeneron Pharmaceuticals P/B Ratio 2024: 2.6×
Regeneron Pharmaceuticals (REGN) P/B ratio in 2024 was 2.6×, contracted from 3.6× the prior year.
Regeneron Pharmaceuticals P/B Ratio 2023: 3.6×
Regeneron Pharmaceuticals (REGN) P/B ratio in 2023 was 3.6×, expanded from 3.4× the prior year.
Regeneron Pharmaceuticals P/B Ratio 2022: 3.4×
Regeneron Pharmaceuticals (REGN) P/B ratio in 2022 was 3.4×, contracted from 3.6× the prior year.
Regeneron Pharmaceuticals P/B Ratio 2021: 3.6×
Regeneron Pharmaceuticals (REGN) P/B ratio in 2021 was 3.6×.
Sector peers by P/B Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/B Ratio — table
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by P/B ratio.
| 3.0× | |
| 2.9× | |
| 2.7× | |
| 2.6× | |
| 2.5× | |
| 2.5× | |
| 2.4× | |
| 2.4× | |
| 2.3× | |
| 1.8× | |
| 1.8× | |
| 1.7× | |
| 1.7× | |
| 1.6× | |
| 1.5× | |
| 1.5× | |
| 1.5× | |
| 1.4× | |
| 1.4× | |
| 1.4× | |
| 1.2× | |
| 1.2× | |
| 1.1× | |
| 1.1× | |
| 0.8× |
- 2.7×
- 2.4×
- 2.3×
- 1.8×
- 1.7×
- 1.4×
- 1.4×
- 1.2×
- 1.1×
- 1.1×
- 0.8×
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric